Research by program

Solid Tumors Bladder cancer • NCT03532451: Phase Ib Feasibility Trial of Neoadjuvant /Lirilumab in Cisplatin-Ineligible Muscle- Invasive Bladder Cancer (PrE0807). Abstract #TPS4594

• NCT03513952: and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma. Abstract #TPS4586

Breast • EAI142: Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer

• TBCRC: A Phase 2 Study of Olaparib Monotherapy In Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes “Olaparib Expanded”

GI • CC9934: Phase II Study of PEGPH20 and (MK-3475) for Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma with High Hyaluronan (HA-HIGH) Expression

• CC9913: HCRN: A Pilot Study Of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma with Preserved Liver Function

Head & Neck • NCT03749460: Nivolumab and and Stereotactic Body Radiation Therapy in Treating Patients with Salivary Gland Cancers. Dual Immune Checkpoint Blockade and Hypofractionated Radiation in Patients with Salivary Gland Cancers

• NCT03691207: A Phase II, Open-label, Single-arm, Multi-center Study of AL101 in Patients with Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations Merkel cell carcinoma Thoracic • NCT03271372: A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Trial of Adjuvant • NCT03228537: Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation (anti-PDL-1 antibody) in Merkel Cell Carcinoma Patients with Clinically Detected Lymph Node Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma. A Feasibility Trial of Neoadjuvant Metastases Cisplatin-Pemetrexed with Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma • NCT03747484: Gene-modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer • NCT03800134: A Phase III, Double blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/ Adjuvant for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer. Phase 1 • NCT03517488: A Phase I Study of XmAb® 20717 (PD-1&CTLA4 bispecific mAb) in Subjects with Advanced Solid Liquid Tumors and Blood Disorders Tumors. Cellular Immunotherapies • NCT02452268: A Phase I/Ib Study of NIZ985 ((hetIL-15) (IL15/sIL-15Ralpha)) Alone and in Combination with PDR001 (PD1 mAb) in Patients with Metastatic Cancers. • FH9922 / RG9218026: An Open-Label, Phase I/II Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004) Prostate cancer • FH9918 / RG9218008: A Phase II, Multi-center Study to Evaluate the Efficacy and Safety of Autologous Tumor • NCT03516812: Bipolar Androgen Therapy Plus Olaparib in Patient with Castration-Resistant Prostate Cancer Infiltrating Lymphocytes (LN-145) for the Treatment of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck • NCT03442556: PLATI-PARP: A Phase II Study of Induction Docetaxel and Carboplatin followed by Maintenance Rucaparib in Treatment of Patients with Metastatic Castration-resistant Prostate Cancer with Homologous Heme Recombination DNA Repair Deficiency • NCT03647800: Study of APVO436 in Patients With AML or MDS Renal cell carcinoma • NCT03834584: A Phase I Study of AG-636 in the Treatment of Subjects with Advanced Lymphoma • NCT03260504: A Phase I Trial of -2 and Pembrolizumab (MK-3475) Combination Therapy for Patients with Advanced Renal Cell Carcinoma

Sarcoma • CC10015: A Phase I/II Study of ABI-009 (nab-rapamycin) with Pazopanib (VOTRIENT®) in Patients with Advanced Nonadipocytic Soft-tissue Sarcomas

• UW18012: A Pilot Study of Oraxol (oral paclitaxel capsules + oral HM30181AK-US tablet) in Subjects with To see a complete listing of our exciting research, Cutaneous Angiosarcoma please visit https://www.seattlecca.org/clinical-trials. To refer a patient, call (800) 804-8824, Monday–Friday 7 am–6 pm PST.